Vertex's diverse pipeline positions it for a growth, despite challenges in launching new drugs like Casgevy and suzetrigine.

Ocular Therapeutix's Elutyx drug delivery platform offers sustained long-term effects. See why OCUL stock is a Buy.

Neuroinflammation drives the progression of neurodegenerative disorders like Alzheimer's, Parkinson's, and multiple sclerosis. Targeting neuroinflammation with small molecules is promising, but ...

The oncology landscape is evolving, with a marked rise in cancer incidence among young adults globally. This challenges the traditional view of cancer as primarily an ailment of the elderly. The ...

Despite uncertainty around who will sit in The White House in January and what ramifications they may bring, the industry’s ...

The biosimilar market continued to grow, with 57 approved biosimilars and 17 reference product biologics as of June 2024. Biosimilars that have seen the fastest uptake have been in oncology, ...

Ebglyss' approval highlights the opportunity that exists in the AD space, and may have potential advantages in efficacy and ...

Australia's Therapeutic Goods Administration (TGA) has said it won't approve Eisai and Biogen's Alzheimer's disease therapy ...

BMB-201 demonstrated dose-dependent efficacy in pain modelsBMB-201 demonstrated similar efficacy to morphine in several pain modelsNEW YORK, Oct.

Researchers from the Critical Analytics for Manufacturing Personalized-Medicine (CAMP) Interdisciplinary Research Group (IRG) ...

The FDA's approval of Bristol Myers Squibb's Cobenfy for schizophrenia opens doors for Reviva's brilaroxazine, a ...

Patent application covers key technology innovations for delivering therapeutic agentsProprietary technology enables precise ...